Aspirin and immunotherapy combo studied for tough breast cancer
NCT ID NCT04188119
First seen Dec 11, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study was designed to see if adding aspirin to an immunotherapy drug called avelumab could help treat triple-negative breast cancer, a type that doesn't respond to hormone therapy. The plan was to give some patients avelumab alone and others avelumab plus aspirin for about 18 days, then compare the effects on the immune system and cancer cells. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.